Jelisaveta Vuletić

Jelisaveta Vuletić

Auto-generated profile, based on publicly available information

Jelisaveta Vuletić


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Srpski medicinski casopis Lekarske komore
Verified
Journal Article
Open access
PDF file
Petar OtaševićPetar Otašević
Petar Otašević
JVJelisaveta Vuletić
Jelisaveta Vuletić
DMDejan Munjiza
Dejan Munjiza
SASvetlana Apostolovic
Svetlana Apostolovic
AIAndrej Ilanković
Andrej Ilanković
NVNikola Vojvodić
Nikola Vojvodić
Introduction/Objective: Insomnia is a common sleep disorder that extends beyond the subjective feeling of poor sleep and represents a state of persistent physiological hyperarousal with important cardiovascular consequences. This review aimed to summarize the pathophysiological links between insomnia and cardiovascular disease and to compare the clinical implications of benzodiazepines and Z-hypnotics in the treatment of insomnia in cardiac patients. Methods: Using a descriptive-comparative approach, we analyzed review articles, meta-analyses, cohort studies, and observational studies addressing the relationship between insomnia, cardiovascular outcomes, and pharmacological treatment, with particular focus on differences between benzodiazepines and Z-hypnotics in cardiac patients. Results: The available evidence indicates that insomnia, through autonomic, neuroendocrine, inflammatory, and metabolic dysregulation, contributes to the development of hypertension, atrial fibrillation, and heart failure, with the greatest risk observed in insomnia with objectively short sleep duration. Longitudinal studies further suggest that persistent insomnia symptoms are associated with greater cardiovascular burden. In therapeutic terms, benzodiazepines in cardiac patients are associated with higher rates of adverse events, including heart failure rehospitalization, sudden cardiac arrest, and cardiovascular mortality, whereas available data on Z-hypnotics suggest a more favorable or neutral profile. Conclusion: Insomnia is a clinically important yet often overlooked cardiovascular risk factor. In cardiac patients, its recognition and treatment should be part of a comprehensive clinical approach, prioritizing non-pharmacological measures and carefully selected pharmacotherapy. When drug treatment is necessary, Z-hypnotics may be considered a more favorable alternative to benzodiazepines, with zopiclone standing out because of its pharmacological and clinical characteristics.

1 January 2026 in Medicinska istrazivanja
Verified
Journal Article
Open access
PDF file
Petar OtaševićPetar Otašević
Petar Otašević
AĐAnastasia Đorđić
Anastasia Đorđić
TKTatjana Karadžić
Tatjana Karadžić
JVJelisaveta Vuletić
Jelisaveta Vuletić
IPIvana Petrovic
Ivana Petrovic
Anemia is a frequently observed comorbidity in patients with heart failure (HF) and it contributes to increased morbidity and mortality. Even though the etiology of anemia in HF patients is polymorphic, chronic inflammation and iron deficiency (ID) are reported as the most frequent underlying causes. Anemia is a strong prognostic marker in both acute and chronic HF, while ID, even in the absence of anemia, has a negative impact on patients' symptoms, functional capacity, and quality of life (QOL). In chronic HF, functional ID is often present due to impaired iron utilization, but it may coexist with absolute ID, where iron stores are depleted. Intravenous (IV) iron therapy has been shown to have a beneficial effect on improving functional status, reducing symptoms, and lowering the rate of hospital readmissions. This has led to its inclusion in the latest guidelines of the European Society of Cardiology (ESC) as a recommended treatment for symptomatic patients with heart failure with reduced ejection fraction (HFrEF). Several studies have also described a consistent trend toward reduced mortality. The aim of this paper is to summarize current knowledge on the importance of ID and the therapeutic effects of iron supplementation in HFrEF patients. Timely recognition and correction of ID should be considered a cornerstone of individualized HfrEF management.